Cargando…

Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein

During the past two decades, the world has witnessed the emergence of various SARS-CoV-2 variants with distinct mutational profiles influencing the global health, economy, and clinical aspects of the COVID-19 pandemic. These variants or mutants have raised major concerns regarding the protection pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Salman Ali, Khan, Alamgir, Zia, Komal, Shawish, Ihab, Barakat, Assem, Ul-Haq, Zaheer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498999/
https://www.ncbi.nlm.nih.gov/pubmed/36142242
http://dx.doi.org/10.3390/ijms231810315
_version_ 1784794900051525632
author Khan, Salman Ali
Khan, Alamgir
Zia, Komal
Shawish, Ihab
Barakat, Assem
Ul-Haq, Zaheer
author_facet Khan, Salman Ali
Khan, Alamgir
Zia, Komal
Shawish, Ihab
Barakat, Assem
Ul-Haq, Zaheer
author_sort Khan, Salman Ali
collection PubMed
description During the past two decades, the world has witnessed the emergence of various SARS-CoV-2 variants with distinct mutational profiles influencing the global health, economy, and clinical aspects of the COVID-19 pandemic. These variants or mutants have raised major concerns regarding the protection provided by neutralizing monoclonal antibodies and vaccination, rates of virus transmission, and/or the risk of reinfection. The newly emerged Omicron, a genetically distinct lineage of SARS-CoV-2, continues its spread in the face of rising vaccine-induced immunity while maintaining its replication fitness. Efforts have been made to improve the therapeutic interventions and the FDA has issued Emergency Use Authorization for a few monoclonal antibodies and drug treatments for COVID-19. However, the current situation of rapidly spreading Omicron and its lineages demands the need for effective therapeutic interventions to reduce the COVID-19 pandemic. Several experimental studies have indicated that the FDA-approved monoclonal antibodies are less effective than antiviral drugs against the Omicron variant. Thus, in this study, we aim to identify antiviral compounds against the Spike protein of Omicron, which binds to the human angiotensin-converting enzyme 2 (ACE2) receptor and facilitates virus invasion. Initially, docking-based virtual screening of the in-house database was performed to extract the potential hit compounds against the Spike protein. The obtained hits were optimized by DFT calculations to determine the electronic properties and molecular reactivity of the compounds. Further, MD simulation studies were carried out to evaluate the dynamics of protein–ligand interactions at an atomistic level in a time-dependent manner. Collectively, five compounds (AKS-01, AKS-02, AKS-03, AKS-04, and AKS-05) with diverse scaffolds were identified as potential hits against the Spike protein of Omicron. Our study paves the way for further in vitro and in vivo studies.
format Online
Article
Text
id pubmed-9498999
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94989992022-09-23 Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein Khan, Salman Ali Khan, Alamgir Zia, Komal Shawish, Ihab Barakat, Assem Ul-Haq, Zaheer Int J Mol Sci Article During the past two decades, the world has witnessed the emergence of various SARS-CoV-2 variants with distinct mutational profiles influencing the global health, economy, and clinical aspects of the COVID-19 pandemic. These variants or mutants have raised major concerns regarding the protection provided by neutralizing monoclonal antibodies and vaccination, rates of virus transmission, and/or the risk of reinfection. The newly emerged Omicron, a genetically distinct lineage of SARS-CoV-2, continues its spread in the face of rising vaccine-induced immunity while maintaining its replication fitness. Efforts have been made to improve the therapeutic interventions and the FDA has issued Emergency Use Authorization for a few monoclonal antibodies and drug treatments for COVID-19. However, the current situation of rapidly spreading Omicron and its lineages demands the need for effective therapeutic interventions to reduce the COVID-19 pandemic. Several experimental studies have indicated that the FDA-approved monoclonal antibodies are less effective than antiviral drugs against the Omicron variant. Thus, in this study, we aim to identify antiviral compounds against the Spike protein of Omicron, which binds to the human angiotensin-converting enzyme 2 (ACE2) receptor and facilitates virus invasion. Initially, docking-based virtual screening of the in-house database was performed to extract the potential hit compounds against the Spike protein. The obtained hits were optimized by DFT calculations to determine the electronic properties and molecular reactivity of the compounds. Further, MD simulation studies were carried out to evaluate the dynamics of protein–ligand interactions at an atomistic level in a time-dependent manner. Collectively, five compounds (AKS-01, AKS-02, AKS-03, AKS-04, and AKS-05) with diverse scaffolds were identified as potential hits against the Spike protein of Omicron. Our study paves the way for further in vitro and in vivo studies. MDPI 2022-09-07 /pmc/articles/PMC9498999/ /pubmed/36142242 http://dx.doi.org/10.3390/ijms231810315 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Khan, Salman Ali
Khan, Alamgir
Zia, Komal
Shawish, Ihab
Barakat, Assem
Ul-Haq, Zaheer
Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein
title Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein
title_full Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein
title_fullStr Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein
title_full_unstemmed Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein
title_short Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein
title_sort cheminformatics-based discovery of potential chemical probe inhibitors of omicron spike protein
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498999/
https://www.ncbi.nlm.nih.gov/pubmed/36142242
http://dx.doi.org/10.3390/ijms231810315
work_keys_str_mv AT khansalmanali cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein
AT khanalamgir cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein
AT ziakomal cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein
AT shawishihab cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein
AT barakatassem cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein
AT ulhaqzaheer cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein